Obermatt
See Similar Stocks →

Nektar

NAQ:NKTR · US6402683063
PharmaceuticalsSmall

360

4
Profit price81
Owner Earnings Yield1
Dividend Yield1
Price/Sales7
EV / Gross Profit10
Price/Book16
Return on Capital19
Cash Return on Capital10
Return on Equity14
EBIT Margin1
Gross Profitability13
Accruals1
Owner Earnings Margin9
Sales growth12
Profit growth13
Reinvestment71
Price momentum96
Debt load43
Refinancing42
Debt Payback1
Liquidity42
Analyst ratings56
Opinion Changes50
Price Target Upside98
Market mood25
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Nektar doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded1990
Employees379
Websitenektar.com
ISINUS6402683063
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
InflammationDiabetesImmunologyGastroenterologyRheumatologyChronic DiseasesOncologyBiotechnologyChemicalHealth CareTherapeutics

Description

Nektar Therapeutics (Nektar) operates as a clinical stage, research-based drug discovery biopharmaceutical company focuses on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, the company direc…

Analysis

Weak and unloved

Nektar Therapeutics is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
11
2023202420252026

All-time high

60

Jan 2024

All-time low

11

Jun 2026

Average rank

41

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
7
49
74
14
Price/Earnings
76
81
81
8
Price/Book
16
28
81
42
Dividend Yield
1
1
1
1
Value (overall)
17
22
9
78

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Nektar with its peers
AnaptysBio
NSQ:ANAB
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Omeros
NMQ:OMER
29
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Adicet Bio
NAQ:ACET
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Equillium
NAQ:EQ
56
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Relmada Therapeutics
NAQ:RLMD
—
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Terns Pharmaceuticals
NSQ:TERN
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →